RECURSION PHARMACEUTICALS IN's ticker is RXRX and the CUSIP is 75629V104. A total of 158 filers reported holding RECURSION PHARMACEUTICALS IN in Q1 2023. The put-call ratio across all filers is 0.85 and the average weighting 0.9%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $169,119 | -1.6% | 22,107 | -3.9% | 0.01% | -16.7% |
| Q2 2023 | $171,832 | +21.7% | 23,003 | +8.7% | 0.01% | +20.0% |
| Q1 2023 | $141,144 | +9.9% | 21,161 | +27.0% | 0.01% | 0.0% |
| Q4 2022 | $128,418 | -44.4% | 16,656 | -23.3% | 0.01% | -50.0% |
| Q3 2022 | $231,000 | +13.2% | 21,707 | -3.8% | 0.01% | +11.1% |
| Q2 2022 | $204,000 | +16.6% | 22,562 | -4.1% | 0.01% | +28.6% |
| Q1 2022 | $175,000 | -24.2% | 23,524 | +50.7% | 0.01% | -22.2% |
| Q4 2021 | $231,000 | +5.5% | 15,606 | +52.3% | 0.01% | -10.0% |
| Q3 2021 | $219,000 | -22.3% | 10,247 | +46.0% | 0.01% | -28.6% |
| Q2 2021 | $282,000 | – | 7,020 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Kinnevik AB (publ) | 10,405,668 | $79,603,360 | 100.00% |
| Data Collective IV GP, LLC | 5,941,120 | $45,449,568 | 43.00% |
| MIC Capital Management UK LLP | 8,451,758 | $64,655,952 | 14.74% |
| MV Management XI, L.L.C. | 788,762 | $6,034,029 | 10.04% |
| ArchPoint Investors | 1,047,386 | $8,012,503 | 3.06% |
| Connective Portfolio Management, LLC | 33,000 | $252,000 | 0.77% |
| PLATINUM INVESTMENT MANAGEMENT LTD | 2,335,132 | $17,863,760 | 0.70% |
| Diametric Capital, LP | 136,331 | $1,042,932 | 0.44% |
| ARK Investment Management | 6,876,598 | $52,605,973 | 0.40% |
| ALLEN OPERATIONS LLC | 217,657 | $1,665,076 | 0.37% |